Abstract
Greystone Research Associates is pleased to announce the publication of
a new market study. Molecular imaging Agents: Technology, Targets and
Commercial Outlook is a comprehensive evaluation and analysis of the
technology and participants driving this evolving healthcare sector.
The report has been designed and developed to provide pharmaceutical company
decision makers, enabling technology providers, discovery tool designers, and
industry strategists with a detailed understanding of the expanding role and
potential of biomarker discovery on drug development and diagnostic medicine.
Provider organization business managers, healthcare administrators and
investors will also benefit from this publication.
Imaging Processes at the Molecular and Cellular Level
A number of challenging opportunities are on the horizon for medical imaging.
Unlike many other sectors of the healthcare industry where technology
successes periodical occur that seem to propel the market forward, these
opportunities are being driven by the migratory advances of academic, public
(government) and commercial research programs.
The potential for molecular imaging is significant. The few successful
molecular imaging agents currently available have evolved from the research
domain. 18FDG was originally developed for research studies of glucose
metabolism in the brain and heart muscle, and is now available in the U.S. and
Europe for cancer imaging. SPECT and PET tracers have been developed to
measure oxidative metabolism, fatty acid and amino acid metabolism, and pre-
and post-synaptic receptor densities. The ability of these first-generation
agents to improve diagnostic and treatment capabilities is now driving a
directed effort to develop the next-generation of molecular agents. To sense
biological processes such as gene expression, angiogenesis, apoptosis or cell
trafficking in vivo, imaging reporter agents that interact specifically with
molecular targets and appropriate imaging systems are currently under
development.
Molecular imaging will greatly reduce the need for animal tissue sampling or
human biopsy when studying the progression of a disease or the follow-up of a
gene therapy. It has the advantage of being non-invasive, and because it can
be repeated many times, it provides both spatial and temporal dimensions to
the understanding of the gene expression of the disease or therapy.
Feature Summary
- Analyzes and assesses emerging imaging diagnostic candidates, their
capabilities, benefits, limitations and potential
- Profiles development-stage imaging agents and examines their clinical
status and commercial prospects
- Analyzes key industry alliances and partnerships by imaging modality, and
examines the impact of next-generation imaging candidates on future imaging
markets
- Profiles market participants, their development activity and business
strategies
- Evaluates the impact of economic, technology, and regulatory factors on
the development and commercialization of emerging imaging agents
Methodology
Research methodology is based on primary research in the form of in-depth
interviews with key market participants, technology developers, distributors,
industry experts, and market influencers, a list that includes regulatory
officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including
trade journal articles, technical literature, industry publications, company
data sheets and published information, and statistical data from government
agencies and trade associations.
Forecasts and projections of market demand and future market activity are
derived using standard modeling and statistical techniques.
About Greystone Research Associates
Greystone Research Associates is a medical technology consulting firm
focused on the areas of medical market strategy, product commercialization,
venture development, and market research. We assist medical and healthcare
market participants in achieving their business objectives through the
creation of detailed development strategies, product commercialization
programs, and comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to
provide timely and insightful information and data on focused market segments,
with the aim of providing market participants with the essential knowledge to
refine and execute their marketing plans and financial targets.
Report Format: This report is available electronic format.
Table of Contents
Executive Summary
Advanced Imaging Agents - Market Dynamics
- Targeted Therapy
- The Potential of Physiological Imaging
- Molecular Imaging - Current Successes
- Market Drivers
- Industry Alignment and Competitive Landscape
- Differential Diagnosis
Diagnostic Imaging Technology
- Candidates and Strategies
- Antibodies
- Conjugated Radioisotopes
- Lanthanide Chelates
- Metabolic Biomarkers
- Optical Probes
- Nanoparticles
- Targeted Imaging Agents
- Activatable Imaging Agents
- Leading Academic/Research Programs/Centers
Imaging Modalities & the Potential of Molecular Imaging
- MRI
- Optical Imaging
- PET
- SPECT
- Ultrasound
The Need for New Imaging Agents
- Disease Detection
- Image-Guided Drug Delivery
- Physiological Process Mapping
- Therapeutic Screening
- Treatment Assessment
Clinical Applications - Near-Term Assessment and Future Impact
- Physiological Visualization
- Angiogenesis
- Apoptosis
- Inflammation
- Disease Detection and Therapeutic Management
- Autoimmunity
- Cardiology
- Neurology
- Oncology
Market Factors
- Guidance, Rules and Regulations
- Clinical Validation
- Alliances & Partnerships
- Complementary Imaging Modalities/Hybrid Systems
Company Profiles
